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Valerie W. Rusch, MD,* and Dorothy J. Giroux, MS†
In this issue of the Journal of Thoracic Oncology, Asamura et al. provocatively suggestthat the number of metastatic lymph nodes (LNs) provides more accurate pathologic
nodal (pN) staging in lung cancer than the current method of considering anatomical
location of involved nodes. They analyzed retrospectively 1659 patients who underwent
resection for non-small cell lung cancer from 2000 to 2006 and classified LN involvement
according to whether metastases were seen in one to two nodes (nN1), three to six nodes
(nN2), or seven or more nodes (nN3). There was no significant difference in overall
survival between pN1 and pN2 according to the current method of N staging based on
whether metastases were identified in peribronchial, interlobar, or hilar LN (pN1) versus
ipsilateral mediastinal LN (pN2). However, multivariate analysis showed that the nN
category was an independent prognostic factor for overall survival.
This study benefits from the inclusion of a relatively large number of patients over a
recent time frame and from an uniform approach to staging by experienced surgeons, although
the analyses raise a few methodological issues. The authors use a “lobe-specific” approach to
N staging, removing and examining by frozen section mediastinal LN known anatomically to
be the first site of drainage for each lobe and only proceeding to removing additional groups
of mediastinal LN if the first one shows metastases. Although this approach is increasingly
accepted in many centers, controversy exists as to whether it yields equivalent staging to
a systematic nodal dissection in all patients. In addition, tumors were staged according the
sixth edition of the tumor-node-metastasis (TNM) classification for lung cancer, which
potentially leads to the inclusion of some patients who would be excluded if the seventh
edition definitions were used (e.g., patients with pleural metastases who would now be
considered to have M1a rather than T4 disease).1,2 The authors also report that analyses
of each nN stage in terms of overall survival across each pT stage did not uniformly reach
statistical significance. This may reflect the very small numbers of patients available for
analysis in the higher stage T subsets. Given the substantial changes in T stage descriptors
from the sixth to the seventh editions, it is difficult to know whether the analyses of nN
stages across individual T stage would be different had the authors used the current
staging system. In addition, the authors do not explain how their nN split points were
selected. Finally, the lack of difference in overall survival in this study based on the
current approach of LN location (i.e., nepN1 versus pN2) is troubling, as virtually every
major analysis during the past three decades has shown this to be statistically significant,
including the very large database of the International Association for the Study of Lung
Cancer (IASLC).3 The lack of prognostic significance in the current study is potentially
explained by the exclusion of worse prognosis N2 disease, specifically patients known to
have “bulky” or “clinical” mediastinal nodal metastases. Only patients who had “minimal”
N2 disease underwent resection and were analyzed for overall survival. Thus, it is
impossible to know how the proposed nN classification extrapolates to the larger
population of patients with N2 disease. Moreover, no attempt is made to apply thispro-
posed classification to clinical staging.Validity in both clinical and pathologic staging
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has been one of the cardinal principles for acceptance of
changes to the TNM staging system.
N staging according to LN anatomical location is
known to yield heterogeneous prognostic groups and has
consistently been a source of dissatisfaction for lung cancer
investigators. As well discussed by Asamura et al., several
alternative approaches to N staging have been proposed,
either the number of involved LN or LN stations. In other
malignancies such as breast, colon, and gastric cancer, the
absolute number of metastatic LNs has long been the ac-
cepted parameter of N staging. For cancers of the esophagus
and gastroesophageal junction, a major shift occurred from
the sixth to the seventh editions of the TNM classification
with the number of metastatic LNs rather than LN anatomical
location now being the basis for N staging. This change
occurred as the result of the analysis of a large international
database.4,5 Interestingly, the split points in that analysis were
precisely those used in this study for nN stages N1, N2, and
N3. It had been hoped that analyses of the retrospective
IASLC database, which formed the basis for the seventh
edition of the lung cancer TNM classification, would lead to
changes in the method of N staging. However, no differences
in survival were seen according to the number of involved LN
stations. Analyses by the number of involved LN “zones,”
which grouped together specific LN stations (e.g., LN at
levels 1–4 were grouped together as “upper zone,” those at
levels 5 and 6 were considered the “aortopulmonary” or “AP”
zone) suggested that N staging might be revised into three
categories including N1a (single N1 zone disease), N1b plus
N2a (multiple N1 or single N2 zone disease), and N2b
(multiple N2 zone disease). This approach to N staging has
the advantage of being easily applicable to both clinical and
pathologic staging. However, even the 2538 pathologically
staged N1 and N2 cases in the IASLC database, far more than
the 456 such patients in this study, proved statistically inad-
equate to recommend a change in the N stage categories
because the number of patients in each proposed N category
available for analysis across each T stage was too small.
Thus, the final recommendation from the IASLC Staging
Committee was to maintain the previous method of N stag-
ing.6 These results emphasize that very large numbers of
patients will be needed in future analyses to make evidence-
based recommendations for revisions of N staging in lung
cancer. It is hoped that the prospective IASLC database to
which patients are now being accrued will provide a large
enough sample size with sufficiently reliable international
data to address current deficiencies in the lung cancer TNM
staging system, including the method of N staging.
Conceptually, at least three new approaches to N stag-
ing could be tested in the prospective IASLC database as well
as other large datasets. These include staging according to the
absolute number of involved LNs as proposed by Asamura et
al.; staging according to the number of involved LN stations;
and staging according to the number of involved LN zones as
suggested by the previous IASLC analysis. Staging according
to the number of involved LN zones takes into account both
LN location and tumor, is probably the easiest approach to
apply clinically as well as pathologically, and the easiest to
implement across practices of varying expertise worldwide.
Staging according to the absolute number of involved LNs,
although theoretically applicable to clinical staging because
of advances in imaging and staging techniques, will demand
a much higher level of precision from radiologists and pa-
thologists as well as clinicians. This may be difficult to
achieve in countries outside Japan where all physicians in-
volved in lung cancer management have raised staging to an
enviable level of accuracy. As noted by Asamura et al.,
reliable reporting of the number of metastatic LNs requires
that the surgeon either submit whole LN or specifically label
a node removed in fragments as a single node. Similar levels
of precision will be required for clinical staging by endobron-
chial ultrasound or mediastinoscopy. Imaging techniques
such as computed or positron emission tomography may not
allow such accurate clinical staging, an issue that was also
controversial in gaining acceptance of the changes in the
seventh edition TNM classification for esophageal cancer. In
addition, as discussed by Asamura et al., evidence-based
guidelines for the total number of LNs required for adequate
staging in patients undergoing resection need to be devel-
oped. Such guidelines were generated for esophageal cancer
through analyses of the international database.7 Current rec-
ommendations suggest that at least six LNs should be re-
moved but this has little scientific basis. In this study,
Asamura et al. found that the mean number of metastatic
nodes in patients with N2 disease was 5.74, which suggests
that six LNs may be a barely adequate number to achieve
adequate staging. This issue needs to be examined further in
future studies.
Although analyses of the ongoing prospective IASLC
international lung cancer database will likely provide the
basis for definitive recommendations for revisions in the next
edition of the TNM classification, studies such as the one
presented in the study by Asamura et al. offer important
hypotheses for testing in larger multicenter datasets. The
authors have performed a thoughtful study that raises impor-
tant questions regarding the lung cancer staging system.
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